Aarti Drugs Limited (NSE: AARTIDRUGS) is a Healthcare company,
ranked #1,265 of 6,774 companies globally and #956 of 2,400 in India on PositoAI,
with a Positivity Score of 22,994.
Its market capitalisation is ₹3,468.72 Cr, P/E ratio is 18.2 and P/B ratio is 2.24.
It has no active red flags (PosiRed) and 1 yellow flag (PosiYellow, 1/10 points): Promoter shares pledged.
For financial statements, ratio trends and score history, Go Deep →
Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
P/B Ratio2.24
P/E Ratio18.2
D/E Ratio0.37
ROE (calculated)12.33%
Owes vs Owns ?0.45× Low₹0.45 owed for every ₹1 it owns · balance sheet Mar 2026
Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium,…
What is Aarti Drugs Limited's P/E and P/B ratio?
Aarti Drugs Limited has a P/E ratio of 18.2 and a P/B ratio of 2.24.
What is Aarti Drugs Limited's debt-to-equity ratio?
Aarti Drugs Limited has a debt-to-equity ratio of 0.37.
How much does Aarti Drugs Limited owe compared with what it owns?
Aarti Drugs Limited owes ₹0.45 for every ₹1 it owns (balance sheet Mar 2026), which is low.
What is Aarti Drugs Limited's Positivity rank?
Aarti Drugs Limited is ranked #1,265 of 6,774 companies globally and #956 of 2,400 in India on PositoAI, with a Positivity Score of 22,994.
Does Aarti Drugs Limited have any SEBI orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Aarti Drugs Limited has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 1/10 points): Promoter shares pledged.
Where can I read the latest news about Aarti Drugs Limited?
Recent headlines about Aarti Drugs Limited from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Aarti Drugs Limited have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Aarti Drugs Limited's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.
0 / 1000
🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.
Disclaimer —
PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.